Search Journal-type in search term and press enter
Social Media-Follow Southwest Journal of Pulmonary and Critical Care on Facebook and Twitter
« A Time-Motion Study of Primary Care Physicians' Work in the Electronic Health Record Era | Main | Quantifying Population-Level Health Benefits and Harms of E-Cigarette Use in the United States »
Tuesday
Mar272018

Impact of Temporary Methotrexate Discontinuation for 2 Weeks on Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomised Clinical Trial

Park JK, Lee YJ, Shin K, Ha YJ, et al.  Ann Rheum Dis. 2018 Mar 23. pii: annrheumdis-2018-213222. [CrossRef]  [PubMed]

Rheumatoid arthritis (RA) is a common disease and methotrexate (MTX) is often used to treat RA. The present study examined whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). In this prospective randomized parallel-group multicenter study, patients with RA on stable dose of MTX were randomized to continue MTX or to hold MTX for 2 weeks after seasonal influenza vaccination. The primary outcome was frequency of satisfactory vaccine response defined as greater than or equal to fourfold increase of hemagglutination inhibition antibody titer at 4 weeks after vaccination against ≥2 of four vaccine strains. The intention-to-treat population included 156 patients in the MTX-continue group and 160 patients in the MTX-hold group. More patients in MTX-hold group achieved satisfactory vaccine response than the MTX-continue group (75.5% vs 54.5%, p<0.001). Although it is late in influenza season in the US, this study suggests that a temporary MTX discontinuation for 2 weeks after vaccination improves the immunogenicity of seasonal influenza vaccination in patients with RA without increasing RA disease activity.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>